Navigation Links
Nuvo Research subsidiary signs collaboration agreement with Fortune Global 500 company
Date:11/25/2008

MISSISSAUGA, ON, Nov. 25 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin, today announced that fqubed, Inc., its San Diego-based research and development subsidiary, has signed a research and development collaboration agreement with a Fortune Global 500 company that develops and markets skin care products. Financial details of the agreement were not disclosed.

"The fqubed technologies have valuable applications beyond our primary focus on pharmaceutical products delivered to and through the skin," said Dan Chicoine, Nuvo's Chairman. "Collaboration agreements such as this allow us to leverage the power of our transdermal screening and high throughput formulation development platforms in complementary areas, and to improve our research capabilities so that we can more effectively develop our own topical drug pipeline."

Under the collaboration, fqubed will expand the scope of its TEMPEST(TM) high throughput experimentation (HTE) platform to evaluate potential formulations for its partner's product portfolio. TEMPEST(TM) is currently used to screen the impact that formulation variations have on the penetration of a drug molecule through skin. TEMPEST(TM) offers testing throughput significantly higher than conventional equipment thereby increasing the likelihood of new discoveries.

"Collaborations with leading third parties validate fqubed's HTE technology leadership position," added John M. Newsam, fqubed's President and Managing Director. "They also allow us to broaden and strengthen our proprietary HTE platforms with input from groups that have extensive and complementary experience with skin-applied products."

Nuvo acquired fqubed in 2005 to increase its ability to develop novel drug products for delivery to or through the skin. The Nuvo subsidiary has discovered molecular penetration enhancer (MPE(TM)) systems suitable for enhancing drug delivery and is advancing a portfolio of prospective new topical pain products.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid(R), a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development center in San Diego, California. For more information, please visit www.nuvoresearch.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Companies consider the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding the future events, many of which are beyond the control of the Companies and their subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual reports, as well as in the Companies' Annual Information Forms for the year ended December 31, 2007. The Companies disclaim any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Companies' ongoing quarterly filings, annual reports and Annual Information Forms and other filings found on SEDAR at www.sedar.com.


'/>"/>
SOURCE Nuvo Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. UCSD researchers identify potential new drug target for chronic leukemia
2. USC researchers identify novel approach for suppressing prostate cancer development
3. Children's National Dedicates New Research Facility
4. Researchers identify new leprosy bacterium
5. CVS/pharmacy Raising Funds for the St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign to Support Expanded Rehabilitation Services Center
6. VivoMetrics LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project
7. Marlo Thomas and St. Jude Childrens Research Hospital(R) Kick Off The 5th Anniversary of the Thanks and Giving(R) Campaign Asking America to Support St. Jude While Shopping this Holiday Season
8. Collexis Launches Innovative Reviewer Finder to Enhance the $30 Billion Health Research Grant Industry
9. Smoking, teens and their parents: New research
10. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
11. Researchers discover strategy for predicting the immunity of vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive ... an innovator in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will ... sell wheelchair accessible vehicles. With this new incentive plan, BraunAbility plans to continue ...
(Date:1/16/2017)... ... January 16, 2017 , ... In ... education and high-level training standards to an international multidisciplinary group of healthcare treatment ... As a way to further its mission at the grassroots level, iaedp launched ...
(Date:1/16/2017)... ... 2017 , ... NexTec Group has been selected as a member of the ... accomplishments in the field of midmarket financial software. , Members of the VAR Stars ... is not based on revenue and those firms chosen represent a wide range of ...
(Date:1/15/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... services. Albertsons Companies is the largest national food and drug chain with ... Accreditation by ACHC reflects Albertsons Companies’ dedication and commitment to meeting national standards ...
(Date:1/15/2017)... Radnor, Pa. (PRWEB) , ... January 15, 2017 , ... ... its newest location in Radnor, Pennsylvania. As construction wraps up on the 14,000+ square ... be The Gravity Vaults sixth location, including three in New Jersey and two in ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... "Vital Signs Monitoring Devices Market by Type and End User: ... global vital signs monitoring devices market size was worth $3,694 ... by 2022, growing at a CAGR of 5.8% from 2016 ... leading regional market in global vital signs monitoring devices industry. ...
(Date:1/16/2017)... , January 16, 2017 ... Derivatives Market by Product Type (Methyl, Ethyl, Hydroxyethyl, ... Foods & Beverages, Surface Coatings & Paints), ... by MarketsandMarkets, the market was valued at ... projected to reach USD 6.41 Billion by ...
(Date:1/16/2017)... N.J. , Jan. 16, 2017   Linde Gas ... all of the assets and business of The Service Center ... equipment repair services to healthcare providers in the Midwest and ... Broadview, Illinois , The Service Center also ... Greenville, South Carolina . Its primary services ...
Breaking Medicine Technology: